Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
183 Results for "
ADC payload
" in MedChemExpress (MCE) Product Catalog:
Products (183)
183 Results for "ADC payload" in MCE Product Catalog:
Art. -Nr.: HY-177585
CAS. Nr.: 3025473-38-2
Forschungsgebiete:
BLD1102 is a linker-load conjugate (Drug-Linker Conjugates for ADC) consisting of a DNA topoisomerase I inhibitor BCPT02 and a protease-cleavable linker. BLD1102 can be used to synthesize ADCs. BLD1102 can be used in cancer research .
Art. -Nr.: HY-132031
CAS. Nr.: 2682939-53-1
Target:
Forschungsgebiete:
Mal-Val-Ala-PAB (C2-glucuronic acid)-DMEA-PNU-159682 is a drug-linker conjugate composed of a cleavable Val-Ala linker and the potent ADC cytotoxin PNU-159682 (HY-16700), which is applicable for ADC synthesis. When conjugated with an anti-CD46 antibody, Mal-Val-Ala-PAB (C2-glucuronic acid)-DMEA-PNU-159682 delivers its payload to CD46-expressing cells, while cathepsin B cleaves the Val-Ala linker to release the payload. ADCs synthesized from Mal-Val-Ala-PAB (C2-glucuronic acid)-DMEA-PNU-159682 drive durable responses in CD46-expressing patient-derived xenograft models of non-small cell lung cancer and colorectal cancer, and a single administration induces complete tumor regression in most models. Mal-Val-Ala-PAB (C2-glucuronic acid)-DMEA-PNU-159682 can be used in the research of non-small cell lung cancer and colorectal cancer .
Art. -Nr.: HY-183253
Forschungsgebiete:
DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors .
Forschungsgebiete:
PBD dimer-2 (compound 2c) is a C8-linked pyrrolobenzodiazepine dimer. PBD dimer-2 can span an extra base pair and cross-link the 5′-Pu-GA(T/A)TC-Py sequence. PBD dimer-2 can be used as a payload for antibody–agent conjugates (ADCs), and it can be used for the research of cancer .
Art. -Nr.: HY-164107
CAS. Nr.: 3028453-70-2
Target:
Forschungsgebiete:
Art. -Nr.: HY-P9994
CAS. Nr.: 2500674-05-3
Synonyms: SBT6050
Forschungsgebiete:
Art. -Nr.: HY-171124
Synonyms: AZD9592
Forschungsgebiete:
Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .
Art. -Nr.: HY-164107A
Target:
Forschungsgebiete:
Art. -Nr.: HY-164763
Target:
Forschungsgebiete:
SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer .
Art. -Nr.: HY-171191
Art. -Nr.: HY-171718
CAS. Nr.: 550356-40-6
Forschungsgebiete:
seco-CBI-PBD dimer is a CBI-PBD heterodimer and a minor groove DNA crosslinker. seco-CBI-PBD dimer exhibits cytotoxicity against human tumor cells at sub-pM to low nM levels, shows low sensitivity to P-glycoprotein-mediated drug resistance, and can serve as an ADC payload. seco-CBI-PBD dimer can be used in studies of uterine cancer, breast cancer, non-small cell lung cancer, etc.
Art. -Nr.: HY-187360
CAS. Nr.: 3087291-81-1
Target:
Forschungsgebiete:
MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine is a cathepsin B-cleavable linker-payload, with Nampt-IN-22 (HY-187336) as its toxin moiety. MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine can be used for the synthesis of ADC .
Art. -Nr.: HY-171509
CAS. Nr.: 2682939-57-5
Forschungsgebiete:
Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27), an agent-linker conjugate for ADC, consists the ADC linker Mal-N(Me)-C6-N(Me) and a potent ADC cytotoxin PNU-159682. Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27) selectively delivers the payload to CD46-expressing cells, where the linker is cleaved by cathepsin B to release PNU-159682, inducing DNA damage and apoptosis. Mal-N(Me)-C6-N(Me)-PNU-159682 shows durable tumor regression in xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) .
Art. -Nr.: HY-145636
CAS. Nr.: 2490556-51-7
Synonyms: AEX4089DC1; MGC018
Target:
Forschungsgebiete:
Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity .
Art. -Nr.: HY-164762
CAS. Nr.: 2924909-11-3
Synonyms: SHR-A1811
Target:
Forschungsgebiete:
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
Art. -Nr.: HY-173070
CAS. Nr.: 2275612-76-3
Forschungsgebiete:
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .
Art. -Nr.: HY-185279
CAS. Nr.: 3042849-33-9
Synonyms: HS-20093; GSK5764227
Forschungsgebiete:
Risvutatug rezetecan (HS-20093; GSK5764227) is a B7-H3-targeting antibody-drug conjugate (ADC). Risvutatug rezetecan binds to B7-H3 on tumor cells and delivers a topoisomerase I inhibitor payload via a tumor microenvironment-responsive cleavable linker. Risvutatug rezetecan is applicable for the research of extensive-stage small cell lung cancer and non-small cell lung cancer .
Art. -Nr.: HY-185427
Synonyms: IMGN-151
Forschungsgebiete:
Opugotamig olatansine (IMGN151) is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC). Opugotamig olatansine comprises antibody Opugotamig (HY-P990935) and linker-payload NMS-P945 (HY-185569). Opugotamig olatansine binds to two independent epitopes of FRα and promotes antibody binding, internalization, and processing. Opugotamig olatansine can be used for the research of FRα-positive ovarian cancer .
Art. -Nr.: HY-184514
Target:
Forschungsgebiete:
TPA (bi (Tos))-γ-Glu (PEG23)-Glu-Val-Cit-PAB-PNU-159682 is a cleavable linker-payload conjugate, in which the payload is PNU-159682 (HY-16700) and the linker is TPA (bi (SH))-γ-Glu (PEG23)-Glu-Val-Cit-PAB (HY-184515). TPA (bi (Tos))-γ-Glu (PEG23)-Glu-Val-Cit-PAB-PNU-159682 is used to generate L1CAM-targeted antibody-drug conjugates (ADCs). TPA (bi (Tos))-γ-Glu (PEG23)-Glu-Val-Cit-PAB-PNU-159682 can be used in the research of metastatic triple-negative basal breast cancer and lung adenocarcinoma .
Art. -Nr.: HY-157763
Target:
Forschungsgebiete:
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
